Recruiting PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT06568094

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Prostate Cancer

Interventions Abiraterone Acetate tablets（II） Docetaxel Injection HRS-1167 tablets HRS-5041 tablets Prednisone Acetate tablets SHR2554 tablets

Updated 7 times since 2024 Last updated: Dec 26, 2025 Started: Sep 25, 2024 Primary completion: Jun 30, 2026 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06568094, this PHASE1/PHASE2 trial focuses on Prostate Cancer and remains actively recruiting participants. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 7 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Apr 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 2 earlier versions

Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harbin, China
• Shanghai, China